Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Infant Behavior & Development|January 17, 2015
The relationship between transitional motor skills and locomotionJulia Looper, Sara Talbot, Allison Link, et al.
Genome Biology|May 7, 2026
10 × Genomics Flex Gene Expression is a powerful tool for single-cell transcriptomics of xenografts modelsOriol Llorà-Batlle, Anca Farcas, Doreth Fransen, et al.
Cancers|August 26, 2023
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft ModelsAnkur Karmokar, Rebecca Sargeant, Adina M Hughes, et al.
Nucleic Acids Research|December 29, 2025
Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cellsJonathan Ribeiro, Kjetil Hansen, Lotte van Beek, et al.
Molecular Cancer Therapeutics|February 2, 2026
Preclinical to clinical translation of pharmacokinetic-pharmacodynamic relationship in EGFR Exon20Ins mutations: a modelling framework for irreversible inhibitorsAdriana Savoca, Diana Zindel, Radoslaw Polanski, et al.
Cell Reports. Medicine|August 26, 2025
AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertionsAisha M Swaih, Sara Talbot, Adriana Savoca, et al.
NPJ Breast Cancer|August 5, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
Genome Medicine|August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsAndrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Molecular Cancer|July 13, 2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitorsJordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, et al.
Molecular Cancer Therapeutics|April 15, 2026
Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancerValentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, et al.
Pageof 2